AF
MRSN

Amalgamated Financial’s Mersana Therapeutics MRSN Stock Holding History

Amalgamated Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$43K Buy
+432
New +$50.5K ﹤0.01% 2495

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Amalgamated Financial's MRSN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Mersana Therapeutics (MRSN) in Q1 2022: 432 shares worth $43K. The stake represents ﹤0.01% of the portfolio and ranks #2495 among its holdings.

128 funds tracked by Wall St. Rank hold MRSN as of Q1 2022.

  • Amalgamated Financial held 432 shares of Mersana Therapeutics worth $43K as of Q1 2022.
  • Mersana Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Mersana Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2495 holding.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.